Version CI-2026-01 · Effective from September 2026 · Replaces the version of September 9, 2025
Applicable to tellmeGen Starter, Advanced, and ULTRA (whole genome sequencing) products, in Individual, Duo, and Family formats, and to the own genetic data upload service (raw data), to the extent that each product, module, or functionality is available in your country in accordance with Annex I.
This Consent forms part of the contract together with the Legal Terms, Privacy Policy, Cookie Policy, Information Updates and Sample Repetition Policy, and Returns, Shipping, and Replacements Policy, all of which are accessible on the Website prior to contracting. Regarding genetic analysis and the processing of your data, this document shall prevail over the others.
In Duo and Family formats, the purchase may be centralized in a single person, but each adult participant must give their own consent individually, identifiably, and traceably before their sample is analyzed.
1. Summary:
This summary does not replace the full text, but captures what matters most. Please read it entirely before accepting.
• We analyze the DNA from your saliva and provide you with reports on genetic susceptibility to certain health conditions, hereditary conditions, pharmacogenetics, ancestry, traits, and wellness, depending on the product purchased and the modules available in your country.
• The information is informative and educational. It is not a diagnosis, it neither confirms nor rules out any disease, and it should not be used on its own to make healthcare decisions.
• Before acting on a health result, consult a healthcare professional and confirm the variant through a validated clinical method in an accredited laboratory.
• We explain the service using educational materials, tutorials, guides, and glossaries, and we make available to you consultations with qualified professionals that you can contract before or after the analysis. You decide whether to use them; they are not mandatory, and your decision is recorded.
• You decide what you want to know and can hide result categories before opening them.
• The analysis may reveal unexpected information, including family relationships different from what you believe.
• Your sample is destroyed within a maximum period of six months. You can download your data and request its suppression, except for what we must retain by legal obligation, which will be blocked and unused.
• The service cannot be contracted by minors. A parent or guardian may do so on their behalf by providing documentary evidence of representation.
• If you authorize research, your pseudonymized or anonymized data may also be used to develop and train artificial intelligence models. This is voluntary, separable, and revocable.
• Only the first consent is mandatory. The others are voluntary, independent of each other, revocable, and do not affect the service or its price.
2. Who provides the service to you
Responsible for the service and the processing of your data: GENELINK, S.L. (commercial brand «tellmeGen»), NIF B98649494, calle Arquitecto Mora 5, floor 2, door 4, 46010 Valencia, Spain. Health authorization no. 11540 from the Department of Health of the Generalitat Valenciana.
• General contact: info@tellmegen.com · Phone: +34 960 090 596
• Exercise of rights and data protection: lopd@tellmegen.com
• Data Protection Officer: dpo@tellmegen.com
• Control authority: Spanish Data Protection Agency (Agencia Española de Protección de Datos - www.aepd.es) or the control authority of your country of residence.
The interpretation service is provided from Spain and laboratory analysis is performed entirely within the European Economic Area at Eurofins (Denmark), GenePlanet (Slovenia), and MGI (Poland), which operate under quality management systems certified in accordance with the ISO standards applicable to their activity.
3. What this service is and what it is not
tellmeGen analyzes the DNA present in your saliva and provides you, through your account, with reports on your genetic susceptibility to certain health conditions, your status as a carrier of hereditary variants, your predictable response to certain medications, your ancestry, and certain personal and wellness traits.
This information has an informative and educational purpose. It is designed for you to know it and be able to discuss it with a healthcare professional.
A tellmeGen report is not a diagnosis. It neither confirms nor rules out any disease, does not replace any clinical test, and should not be used on its own to make healthcare decisions, start or stop treatments, or modify the dose of a medication.
Having a genetic susceptibility means that certain variants in your DNA have been statistically associated with a higher or lower probability of developing a condition. It does not mean you will develop it, nor that you are free from it if the report does not show those variants. Genetics is only one of the factors involved, along with age, environment, habits, and chance.
The service is contracted freely, by the user's own decision and without medical prescription or clinical indication. tellmeGen does not provide healthcare through the reports nor does it establish a doctor-patient relationship with you by contracting them.
4. What each product includes
• Starter: ancestry, personal traits, and wellness. Microarray technology.
• Advanced: all of the above plus genetic susceptibility to health conditions, hereditary conditions (carrier status), and pharmacogenetics. Microarray technology, with statistical imputation where applicable.
• ULTRA: the same content as Advanced, obtained through whole genome sequencing with an approximate target average coverage of 30×. This does not imply 30× coverage at all positions in the genome or the detection of all regions or variant types, but it allows for the study of a broader spectrum of variants, including rare variants.
The content and scope of the reports may vary depending on the product version, methodological updates, new scientific evidence, and the modules available in your country. The date appearing on each report indicates the applicable version.
5. How the process works
You collect your own saliva sample following the kit instructions and send it to the laboratory. There, DNA is extracted and analyzed via microarray or sequencing, depending on the product contracted. Afterwards, our software processes the data, identifies the variants, and automatically generates your reports, which become available in your account.
The quantity and quality of the DNA obtained, as well as the collection and transport of the sample, influence the validity of the analysis. If a sample is deemed inadequate for reasons not attributable to you, we may offer you a repetition in accordance with the current repetition policy, visible on the platform prior to contracting.
6. What you can expect from the service
• Gain information about your own DNA and better understand why certain conditions are more or less likely in your case.
• Have a documented starting point to speak with a healthcare professional.
• Pharmacogenetic guidance that your doctor can take into account when evaluating a treatment.
• Information about your ancestry and traits.
• Information that may be useful for your biological family members.
7. Limitations you should know before accepting
7.1 Results are probabilistic
Genetic susceptibility results are based on published statistical associations and do not predict whether or not you will develop a condition. They do not express certainty nor do they replace the evaluation of your personal and family history.
7.2 False positives, false negatives, and residual risk
No genetic technique is infallible. A positive result that is not subsequently confirmed may occur (false positive), or a result that fails to detect a variant actually present (false negative). A result without reportable variants reduces, but does not eliminate, the probability. The detection rate varies depending on the gene, the variant type, and your ancestry. Therefore, no result should be considered conclusive without the confirmation described in section 8.
7.3 Technical limitations
In microarray-based products, analysis is limited to predefined markers, and any expansion by statistical imputation depends on the methods and reference populations used: these variants are not measured directly, they are inferred.
In whole genome sequencing, target average coverage is not achieved uniformly across all positions, and there are regions and variant types that are difficult to detect, including copy number variations, complex or balanced rearrangements, repeat expansions, complex haplotypes, pseudogenes, and low-complexity or high-homology regions.
The analysis is performed on saliva and is primarily designed for germline variants. It is not validated for the systematic detection of somatic variants or low-proportion mosaicisms.
7.4 Scope per gene
In Advanced, a specific set of variants is assessed, which does not cover all possible ones or all structural alterations of a gene. ULTRA allows the analysis of much broader regions of the genome and the included genes, but does not guarantee the complete reading of each region or the detection of all variant types. In no case does the absence of findings exclude the existence of other relevant variants.
7.5 Variants of uncertain significance (VUS)
Ordinary reports include only variants with sufficient evidence to be classified as pathogenic or likely pathogenic according to current criteria. Variants of uncertain significance, those whose effect on health is not known with sufficient evidence, are not included in the ordinary report, although the analysis may detect them.
If you explicitly request it, you can separately contract a specific report of variants of uncertain significance at the price indicated on the platform. This report is exploratory in nature: it should not be used to make healthcare decisions, and its content may change as scientific evidence evolves.
7.6 Science changes
The classification of a variant may change over time. We may update your reports when evidence warrants it and the functionality is available in your plan, but we do not assume the obligation to contact you individually every time a change occurs.
7.7 Ancestry
Estimates are probabilistic and depend on available reference databases; world regions with lower representation show lower resolution. Genetic ancestry is not equivalent to citizenship, legal identity, or documented genealogy.
7.8 Pharmacogenetics
It describes how certain variants can influence the metabolism of or response to a drug, but does not solely determine its efficacy or safety. Age, renal and hepatic function, other diseases, drug-drug interactions, and dose are determining factors. In some genes, the identification of complex haplotypes, duplications, deletions, or hybrid alleles requires additional techniques not included. Never modify your medication based on a report.
7.9 External files and third-party services
If you upload a genetic data file obtained from another provider, the reliability of our reports depends on that file, which we do not control. If you download your data and use it in third-party services, interpretations may differ from ours: we do not guarantee its accuracy nor do we provide support on them.
7.10 Security
We apply strict technical and organizational measures, but no information system is completely immune to risks.
8. Confirmation before any healthcare decision
Before a tellmeGen result is used to make a healthcare decision, two conditions must be met:
• That a qualified healthcare professional evaluates it in the context of your clinical and family history.
• That the specific variant upon which the decision depends is confirmed through a validated and independent clinical method, appropriate to the variant type, in an accredited laboratory.
You acknowledge that you have been informed of this double requirement and that you assume it. GENELINK is not responsible for clinical decisions adopted without the intervention of a healthcare professional or without such confirmation.
9. Prior information, educational materials, and professional consultations
9.1 What we provide you before contracting. This document, together with the description of each product, frequently asked questions, and informational materials on the Website and platform, explains the nature, purpose, scope, advantages, limitations, alternatives, and possible consequences of the service. It constitutes prior and pre-analytical information and you declare that you have read and understood it before accepting.
9.2 Minimum content of information. We gather here, in a single place, the points about which you must be informed prior to a genetic analysis:
• The purpose of the analysis: informative and educational, depending on the product contracted (sections 3 and 4).
• Its advantages, risks, limitations, and alternatives (sections 6 and 7).
• The place where the analysis is performed and the destination of the biological sample upon completion (sections 2 and 15).
• The identity of those who will have access to non-anonymized results (sections 19, 20, and 21).
• The possible significance of the results for you, the alternatives you can choose, and your right to decide whether or not you wish to know them (sections 8 and 10).
• The possibility of unexpected discoveries and their possible significance, and your right to decide whether you wish to know them (section 11).
• The implication that results may have for your biological family members (section 11.2).
• The follow-up we offer you once results are issued (section 9.4).
9.3 Educational materials. On the platform, you have permanent and free access to tutorials, guides, glossaries, explanations of each section of the report, and educational resources, designed so that you can understand your results without prior knowledge of genetics.
9.4 Consultations with qualified professionals. tellmeGen maintains a consultation service available with professionals qualified in genetics, which you can contract both before sending your sample and after receiving your results, through the channels enabled on the platform. This service is governed by its own conditions, is informative and educational in nature, does not constitute a medical act or emergency service, and does not replace diagnosis, follow-up, or treatment by a healthcare professional.
9.5 Your decision. Before accepting this Consent, you are expressly informed of the availability of these consultations. You freely decide whether you wish to use them or continue without them, and this decision is recorded along with your consent. Contracting the service is not conditioned on using them, and you can request them at any subsequent time.
9.6 Scope. Neither the platform materials nor the consultations turn the reports into a clinical diagnosis, nor do they eliminate the need for confirmation tests in section 8. In countries where local regulations require a specific professional intervention, the provisions of Annex I shall apply.
10. Your right not to know
10.1 You decide what information you wish to receive. You can choose not to know all or part of the health content of your report and you can change your mind later.
10.2 From your account, you can hide entire categories of results before opening them. You can also request us at any time, by writing to lopd@tellmegen.com, not to be shown a specific category.
10.3 This preference does not prevent communications strictly necessary by legal obligation, product safety, correction of an error, or to prevent a serious risk; in such cases, we will limit ourselves to essential information.
11. Unexpected findings and secondary findings
11.1 A genetic analysis may reveal information you did not expect: kinship relationships different from what you believed, consanguinity between parents, or genetic susceptibilities you were not looking for. Such information can affect you and your family emotionally and cannot be undone once known.
11.2 Results may have implications for your biological relatives, who share part of your DNA and have not given consent. Keep this in mind before sharing your reports.
12. Responsible use and prohibited uses
You undertake not to use the reports, nor provide them to be used, for the following purposes:
• Employment, hiring, or promotion decisions.
• Insurance underwriting, pricing, or exclusion.
• Immigration or nationality procedures.
• Determination of legal filiation, paternity tests, or any forensic or judicial purpose.
• Any discriminatory or unlawful purpose.
Nor may you send samples or data of another person without their valid consent or without holding accredited legal representation, nor impersonate a third party. Breach of this section may result in suspension or cancellation of the account and withdrawal of access to reports.
13. Who can contract. Duo and Family formats
13.1 Contracting requires being 18 years of age or older and having the capacity to consent.
13.2 In Duo and Family, the purchasing person can manage the order and logistics, but cannot consent on behalf of another adult. Each adult participant receives this Consent, accepts it individually from their own identification, and decides separately on voluntary options.
13.3 We will not initiate analysis of a participant's sample until their individual acceptance is recorded. If it is not recorded within 30 calendar days of sample receipt, we will remind them and, failing that, cancel that analysis and apply the Returns Policy.
13.4 Each adult participant is the owner of their own account and data. The purchaser does not obtain access to the results of other participants unless they explicitly authorize it from their account.
14. Minors and persons requiring support for the exercise of their capacity
14.1 A minor cannot contract the service or register themselves.
14.2 The service can only be contracted for a minor by their father, mother, or legal guardian, who acts on their behalf, assumes account ownership, and is responsible for compliance with this Consent.
14.3 Mandatory accreditation. Before processing the sample, you must provide through the platform:
• Valid identity document or passport of the authorizing person.
• Identity document, passport, or birth certificate of the minor.
• Family book, literal birth certificate, or judicial guardianship or custody resolution accrediting the link or representation.
If parental authority is shared, signed authorization from both parents is required, unless there is a judicial resolution attributing that decision to only one, in which case it must be provided. Documents drafted in a language other than Spanish or English must be accompanied by a translation.
14.4 This verification responds to our duty to make reasonable efforts to verify that the consenting party effectively holds parental authority, guardianship, or support. We do not initiate analysis until verifying this documentation. If it is not provided or is insufficient within 30 calendar days of order receipt, we will cancel the service and apply the Returns Policy.
14.5 Accrediting documentation is kept solely as proof of legitimation, with restricted access for authorized personnel, while the account remains active and during liability limitation periods. It is not used for any other purpose.
14.6 Scope of a minor's report. Following international practice in genetics, minor reports do not issue sections on genetic susceptibility to health conditions, hereditary conditions, or pharmacogenetics. The report includes ancestry, personal traits, and wellness. The reason is to preserve the minor's right to decide for themselves, when adults, what genetic health information they wish to know.
14.7 The authorizing person undertakes to explain the content of this document to the minor in a manner appropriate to their age and maturity, and to take their opinion into account.
14.8 Upon turning 18, the interested person may request account ownership. From that moment, they decide for themselves, accept this Consent in their own name, can request the issuance of health sections, and exercise all rights, including suppression. The access of their former representative ceases with that change of ownership.
14.9 Persons with support measures. When there is a judicial resolution or support measures deed concerning decisions of this nature, the same accreditation rules of section 14.3 will apply, replacing filiation documentation with the document establishing support and its scope. The person providing support must inform the person and respect their will, wishes, and preferences.
15. Your saliva sample
Your sample is used exclusively to provide the contracted service. It is destroyed within approximately 60 to 120 days from the issuance of your results and, in any case, before six months, barring a different legal obligation. It is not kept in a biobank nor transferred to third parties for other purposes.
16. Conservation of your data, tellmeGen+, and mandatory archive
16.1 Starter and Advanced. Your results and reports remain accessible while your account is active. You can request suppression at any time.
16.2 ULTRA. The initial period of included access and storage is indicated before contracting. From the fourth month, maintenance of access, active storage, interpretation updates, and re-analyses depend on the current tellmeGen+ plan. If the subscription expires, there is a 12-month grace period during which you can reactivate it and recover access.
16.3 Before the grace period ends, we will notify you by email to the last verified address of your account at six months, two months, one month, one week, and one day in advance, and we will send a final notice once finished, prior to any deletion. Throughout the grace period, and in any case for a minimum of 365 days from subscription termination, we will keep your raw data and reports available for download in a standard and readable format. After that period, we may delete working copies and those intended for your access, confirming this in writing.
16.4 Mandatory archive. Termination of tellmeGen+, suppression at your request, or account closure do not extend to information we must retain by legal, health, product quality, tax obligation, or for defense against claims. This information remains blocked, with restricted access, is not used for any other purpose, and is deleted when the applicable term expires. This archive does not depend on subscription payments nor entails any cost to you.
16.5 Backup copies are kept isolated and deleted or overwritten according to ordinary cycles, with a maximum target of 90 days from operational deletion, barring the mandatory archive of section 16.4.
17. Upload of own genetic data (raw data)
If instead of contracting a kit you upload a genetic data file obtained from another provider, this Consent applies equally, with the following particularities:
• You declare that the file corresponds to your own DNA or that of the person you legally represent, and that you are authorized to transfer it to us.
• We do not verify the identity of the person to whom the file belongs nor the quality of the original analysis.
• The scope of reports we can generate depends on markers contained in the file and may be significantly smaller than our products.
• Section 7 limitations apply more intensely to this service, and section 8 double confirmation is especially necessary.
18. DNA Connect (connection with genetic relatives)
18.1 It is a voluntary function and disabled by default. You can activate it upon accepting this Consent or later at any time from your account. In both cases, activation requires an affirmative action by you, separate from the main consent, and before completion, you are informed which elements of your profile other users will see, what information is shared, and how contact works between them.
18.2 If activated, other users who have also activated it and share DNA segments with you will be able to see and contact you under conditions you choose.
18.3 It may reveal family relationships you were unaware of, including absence of expected kinship, and such information can affect third parties. Once known, it cannot be undone.
18.4 You can deactivate it at any time from your account, with the same ease as activation. Deactivation removes your profile from the comparison index and prevents new connections, but does not delete information already shared voluntarily with another user.
19. Professional Access
19.1 You can authorize a healthcare professional to consult your reports. Authorization is given upon activation, identifying recipient, scope of information, and duration.
19.2 You can revoke it at any time from your account. Revocation prevents new consultations, but does not affect information that professional already downloaded or incorporated into your clinical record, which remains subject to their own professional obligations.
20. Research and development (voluntary)
20.1 Participation in research is voluntary and separable from the rest of the service: it does not condition provision, scope, or price. It is given via specific authorization marked upon contracting and withdrawable at any time.
20.2 Scope of authorization. If granted, we may use your genetic and health data, pseudonymized or aggregated, in research and development projects comprising:
• (a) tellmeGen internal research and improvement: validation and refinement of algorithms, models, reports, and knowledge bases;
• (b) external scientific projects with universities, healthcare centers, scientific societies, or non-profit organizations;
• (c) research, validation, or development projects with companies, industry, or other commercial collaborators, including commercial collaboration agreements with universities and companies.
20.3 In any of these areas, processing may include development, training, validation, and improvement of analytical models and artificial intelligence systems.
20.4 Projects use minimized, pseudonymized, or anonymized data. Directly identifying information is not communicated. Each project determines whether collaborator acts as processor, joint controller, or independent controller, with appropriate contracts, guarantees, and explicit prohibition of re-identification.
20.5 We may combine data covered by this authorization with each other and with those from other tellmeGen services you contracted and authorized, when necessary for described purposes. AI models and systems are developed on pseudonymized or anonymized data and designed/verified not to allow reconstruction or re-identification of a specific person's genetic data.
20.6 Research may result in publications, algorithms, AI models, knowledge bases, patents, products, or services, and may involve economic consideration for tellmeGen or collaborators. Barring specific written agreement, participation grants no economic rights to those results.
20.7 You may withdraw authorization easily via account or writing to <lopd@tellmegen.com>, without explanation, affecting no contracted service. Withdrawal prevents future inclusions and ends future processing based on it. It does not affect lawfully performed processing prior to withdrawal, already published publications, legal obligations, irreversibly anonymized data, or already trained models whose individual extraction is technically impossible.
20.8 We will communicate the withdrawal to collaborators who received your data under this authorization, unless impossible or requiring disproportionate effort. Upon request, we will inform you of whom it was communicated to.
20.9 Irreversible anonymization implies that we can no longer reasonably link such data to you; therefore, they cannot be located or suppressed individually.
21. Data protection information
21.1 Controller. GENELINK, S.L., with contact details in section 2.
21.2 Data categories. Identifying and contact data, contracting and billing data, biological sample, genetic data, responses provided in questionnaires, platform usage data, and, when contracted for a minor or a person with support measures, accrediting documentation from section 14.3.
21.3 Purposes and legal bases:
• Provide the contracted service and issue reports: contract execution (art. 6.1.b GDPR) and explicit consent for processing genetic data (art. 9.2.a GDPR).
• Attend to queries and provide accompanying services of section 9: contract execution.
• Comply with legal, health, quality, product vigilance, and tax obligations, and preserve mandatory archive of section 16.4: legal obligation (art. 6.1.c GDPR).
• Verify identity, legal representation, and support measures, prevent unauthorized analyses, and accredit consent validity: compliance with applicable legal obligations (art. 6.1.c GDPR) and, when no specific obligation exists, documented legitimate interest of GENELINK and represented person in preventing illicit or fraudulent uses (art. 6.1.f GDPR). Retention of proof of consent and representation is further supported by formulation, exercise, or defense of claims (art. 9.2.f GDPR).
• Research and development, including training of AI models and systems in fields described in section 20: specific and separable consent (arts. 6.1.a and 9.2.a GDPR).
• DNA Connect: specific consent given upon accepting this Consent or activating later from account. Professional Access and secondary findings: specific consent given upon activation (arts. 6.1.a and 9.2.a GDPR).
• Platform security, fraud prevention, and defense against claims: legitimate interest (art. 6.1.f GDPR).
21.4 Consent and contract. Consent to analyze DNA and issue reports is essential: without it, service provision is technically impossible. Other consents are independent, do not condition service or price, and can be withdrawn separately.
21.5 Recipients and processors. We work with genetic analysis laboratories, hosting and infrastructure providers, logistics operators, payment gateways, and support tools, bound by data processing contracts under art. 28 GDPR. You can request the specific list of current processors by writing to lopd@tellmegen.com.
21.6 International transfers. Genetic analysis and data storage take place within the European Economic Area with providers in categories identified in section 21.5. If any accessory function implies processing outside the EEA, it will rely on an adequacy decision by the European Commission or standard contractual clauses with complementary measures, and we will inform you.
21.7 Retention periods. Sample per section 15. Genetic data and reports per section 16. Billing and contracting data during legal tax and commercial limitation periods. Consent acceptance record and accrediting representation documentation while liability can derive.
21.8 Automated decisions. Report generation is automated: software identifies variants in DNA and associates them with knowledge base contents created by our genetics team. This treatment produces no legal effects or significant effects on you since reports are informational and do not determine healthcare decisions on their own. You can request review by a genetics team member via lopd@tellmegen.com.
21.9 Your rights. Access, rectification, suppression, limitation, opposition, data portability, and withdrawal of consent at any time via lopd@tellmegen.com. We respond within one month. Withdrawal of DNA analysis consent stops service and entails genetic data suppression, barring mandatory archive under 16.4. Complaints can be filed with the control authority.
21.10 Security and data breaches. Appropriate technical and organizational measures applied, including pseudonymization, encryption, and access controls, alongside a data protection impact assessment. High-risk security breaches will be communicated without undue delay.
22. Liability
22.1 tellmeGen is liable for proper service provision as described and diligence in data processing.
22.2 tellmeGen is not liable for: healthcare decisions adopted without professional evaluation and confirmation under section 8; third-party interpretations from raw data; inaccuracies in external files provided by you; use of reports for prohibited purposes under section 12; consequences of providing reports to third parties.
22.3 Limitations do not exclude or limit liability for willful misconduct or gross negligence, mandatory consumer rights under your country's laws, or manufacturer liability under product regulations.
23. Change of control, corporate restructuring, and succession
23.1 GENELINK may undergo corporate operations such as mergers, spinoffs, business branch contributions, financing operations, or business/share transfers.
23.2 During negotiation/audit, individually identifiable genetic records are not shared. Information is limited to aggregated, statistical, or pseudonymized data without individual genome access, under confidentiality agreements.
23.3 If materialized, the acquiring entity subrogates into the controller position bound by this Consent and your configured preferences.
23.4 If the new controller intends processing for materially different purposes, prior information and valid legal basis or new consent must be obtained.
23.5 In insolvency or liquidation, genetic data may only transfer under service continuity and equivalent guarantees. Otherwise, data will be suppressed or anonymized, barring mandatory archive.
23.6 Operations do not alter rights and are documented in compliance records.
24. Withdrawal and returns
The right of withdrawal is 14 calendar days under applicable consumer law and our Returns, Shipping, and Replacements Policy. When contracting, you expressly request performance to begin during the withdrawal period. If withdrawing after commencement but before completion, proportional payment for services rendered may be due; the right lapses once fully executed where applicable. Sealed physical goods unsuitable for return due to health/hygiene lapse after unsealing where applicable. Mandatory consumer rights remain unaffected.
25. Incidents, claims, and product safety
Report errors, kit incidents, or safety issues to info@tellmegen.com. We log and analyze communications within our quality management system and adopt corrective measures. Competent authorities may also be contacted.
26. Availability by country
26.1 Availability checked prior to purchase based on country of residence, purchase location, sample collection place, laboratory, and result delivery place.
26.2 tellmeGen may prevent contracting, withdraw modules, adapt circuits, or cease service in a country unable to meet local requirements via platform technical controls.
26.3 Annex I summarizes known particularities. It is not exhaustive; platform operational matrices determine applicable circuits.
27. Modifications to this Consent
27.1 Document version-coded. Updated for legal, technical, or product changes.
27.2 If changes expand processing purposes or affect consents, re-acceptance is required before continuing.
27.3 Clarifications communicated accordingly. Accepted versions viewable via account; history requestable via info@tellmegen.com.
28. Languages
Shown in selected language and Spanish. Spanish text is original; translations provided for convenience. In case of discrepancy, Spanish version prevails unless mandatory local laws dictate otherwise.
29. Governing law and jurisdiction
Governed by Spanish legislation, GDPR, Organic Law 3/2018, Biomedical Research Law 14/2007, and Patient Autonomy Law 41/2002, without prejudice to mandatory consumer protection laws of your habitual residence.
30. Electronic record of consent
Upon acceptance, independent records are kept per participant: identification, version code, text hash, date/time, language, country, contracted product, consultation info (9.4), and voluntary choices. Accessible and downloadable from account.
Consents
Adult participants give individual consent upon kit registration. Checkboxes are unchecked. First two mandatory; others voluntary, independent, and revocable.
☐ Mandatory. I have read and accept the Legal Terms and policies forming part of the contract.
☐ Mandatory. I have read and understood the Informed Consent and give explicit consent for tellmeGen to analyze my sample and process genetic data to provide service. I declare I am 18+ or an accredited legal representative. Genetic consultation options noted; continuing without for now.
☐ Voluntary. I want to advance science and treatments: authorize use of genetic/health data in pseudonymized/aggregated research projects, including AI training and commercial partnerships.
☐ Voluntary. Receive updates and special offers. Unsubscribe anytime.
☐ Voluntary. Activate DNA Connect to find genetic relatives within tellmeGen community.
Secondary findings preferences in ULTRA and Professional Access managed separately from account.
Annex I. Country particularities
Forms part of Consent; summarizes operating rules.
A. Countries where service is not provided
France. Services not offered; platform prevents ordering and delivery.
B. Countries with additional information or counseling requirements
Spain, Portugal, Italy, Austria, Norway, and Switzerland require additional info/counseling rules. Platforms provide free educational materials, active consultation offers, and GENELINK services registration (#11540).
C. Germany
Permanent free materials and consultation offers provided. Strongly recommended to discuss results with a licensed German doctor.
D. Rest of countries
Additional requirements checked prior to contract.
Annex II. Glossary
DNA. Molecule containing genetic info.
Variant. Difference in DNA sequence.
Genome. Complete set of DNA.
Microarray. Predefined marker technique.
Whole Genome Sequencing (WGS). Comprehensive genomic analysis technique.
Statistical imputation. Method estimating unmeasured variants.
Carrier. Person carrying a hereditary variant.
Variant of uncertain significance (VUS). Variant with unclear health effect.
False positive. Incorrectly detected variant.
False negative. Undetected actual variant.
Pharmacogenetics. Study of genetic drug response.
Genetic susceptibility. Statistical probability of condition.
Pseudonymization. Replacing identifiers with code.
Anonymization. Irreversible unlinking process.